CDT Equity Inc. Warrant closed at $0.01 on Sep 25, down 2.50%, 40.9% below its highest close since Sep 25. Volume of 10.8K shares was 0.62× its 20-day average (below normal).
Split-adjusted performance: +24.5% over one month, +53.9% over six months.
Short interest was 100.4K shares at the Sep 15 settlement, down 3.5% from the prior report (9.5 days to cover).
No reported quarters with price history yet.
Percentile among 423 companies (100 = best)
Industry medians: 6-month return −2.9%, revenue growth +6.4%, net margin −41.2%, P/E 16.2×.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
